Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study
https://doi.org/10.21516/2072-0076-2018-11-1-36-40
Abstract
Proliferative vitreoretinopathy is a multifactorial pathological process of formation of epiretinal membranes on the surface of the retina. The main method of treatment of this disease is vitreoretinal surgery. To increase the effectiveness of treatment, intravitreally administered antiproliferative drugs are used. Purpose: to study the effect of intravitreally administered medication Melphalan in varied concentrations on the retina and retinal pigment epithelium (RPE), in the experiments on rabbits. Materials and Methods. An experimental morphological study was performed on 28 eyes of 14 Chinchilla rabbits, divided into 4 groups depending on the concentration of Melaphan (0.02 mg, 0.01 mg, 0.0075 mg and 0.005 mg) administered intravitreally once. Results. Four types of morphological changes in the retina and RPE are described, depending on the medication dose administered. The target of Melphalan accumulation in the retina is RPE, which brings about metabolism disorders in the outer layers of the retina and the appearance of atrophic foci. The dynamics of these foci and their reversibility is discussed. Conlusion. The study of morphological changes of the retina in cases of introvitreal administration of Melphalan showed that they are dose-dependent. The minimum retinal toxicity is observed when low concentrations of the drug are used: 0.0075 and 0.005 mg. For citation: Khoroshilova-Maslova I.P., Leparskaya N.L. Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study. Russian ophthalmological journal. 2018; 11 (1): 36-40. doi: 10.21516/2072-0076-2018-11-1-36-40 (In Russian).
About the Authors
I. P. Khoroshilova-Maslova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
N. L. Leparskaya
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
References
1. Sadaka A., Giuliari G.P. Proliferative vitreoretinopathy current and emerging treatments. Clinical ophthalmology. 2012; 6: 1325-1333. doi: 10.2147/OPTH.S27896
2. Mukai A., Koozauskas A. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am. J. Pathology. 2011; 179: 2931-40. doi: 10.1016/j.ajpath.2011.08.043
3. Francis J., Schaiquevich P., Buiatrago E. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthallmology. 2014; 121(9):1810-7. doi: 10.1016/j.ophtha.2014.03.028
4. Chassemi F., Shields C. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch. Ophthalm. 2012; 130(10): 1268-71. doi: 10.1001/archophthalmol.2012.1983
5. Smith S.J., Smith B.D. Evaluating risk extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br. J. Ophthalm. 2013; 97(10): 123-6. doi: 10.1136/bjophthalmol-2013-303188
6. Francis J., Marr B., Brodie S., Abramson D.H. Anterior ocular toxicity of intravitreous melphalan for retinoblastoma. JAMA Ophthalmol. 2015; 133(12); 1459-63. doi: 10.1001/jamaophthalmol.2015.3119
7. Серик Г.И., Давыдов Д.В., Грачев Н.С. и др. Современные тенденции в лечении ретинобластомы ( по материалам образовательных лекций на Конгрессе SIOP-2015, Кейптаун, ЮАР, 8-11 октября 2015 г.). Российский журнал детской гематологии и онкологии. 2016; 3: 64-6. doi: 10.17650/2311-1267-2016-3-1-64-66
8. Яровой А.А., Горшков И.М., Ушакова Т.Л. Интраокулярная хирургия с ирригацией мелфалана в лечении гемофтальма на единственном глазу у ребенка с ретинобластомой (клинический случай). Современные технологии лечения витреоретинальной патологии. 2014; 1: 119-20.
9. Shaiquevich P., Buitrago E., Taich A., et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinic models and retinoblastoma patients. Invest Ophthalmol. Vis. Sci. 2012; 53(7): 4205-12, doi: 10.1167/iovs.12-9501.
Review
For citations:
Khoroshilova-Maslova I.P., Leparskaya N.L. Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study. Russian Ophthalmological Journal. 2018;11(1):36-40. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-1-36-40
Views:
769
Email this article 